Key Takeaways
- API business transformed overnight: The carve-out into RPG Active Pharma, the Invascent partnership, and the acquisitions of Actis and Raghava create a scaled API platform with ~505 kg installed capacity, a 4x jump from the legacy base.
- A ₹700 crore bet on API leadership: Management committed ₹700 crore to be deployed over 12–15 months for acquisitions and capacity, targeting a 25%+ growth CAGR and a ₹1,000 crore revenue aspiration over 5–6 years.
- Domestic formulation is the quiet compounder: The 70%-of-revenue DF business grew 16%, 1.8x the market, making RPG the fifth fastest growing pharma company in India and lifting its IPM rank from 62 to 15.
- Acquired assets carry near-term margin pressure: Actis revenue fell from ₹70 crore to ₹48 crore on intermediate price erosion, and management flagged initial margin pressure post-acquisition, though sustainable margins are targeted in the mid-20s.
- What to watch next quarter: The pace of fund deployment from the ₹700 crore commitment, any disclosure of separate API financials, and whether the new cardiology and urology division gains traction.
The API Platform Build
- Structural logic: The API business transfer into a subsidiary was driven by global supply chain diversification (China plus one), PLI schemes, the Make in India push, increasing regulatory expectations, and growing demand for reliable manufacturing partners.
- Scale transformation: Through the acquisitions of Actis and Raghava, the API business transformed from ~110 kg capacity at a single site to ~505 kg installed capacity, employee strength from ~217 to 500+, R&D scientists from 28 to 53, products from 14 to 45+, customers from 123 to 250+, and pipeline molecules from 12 to 28.
- Invascent partnership: The healthcare-focused PE investor will hold 40% in RPG Active Pharma on a fully diluted basis, with the first tranche of ~₹243.33 crore already raised; the PE firm will have board representation on the RPG board and contribute governance, sector expertise, and strategic guidance.
- Dedicated leadership: Deepak Shukla has been onboarded as dedicated CEO for the API business, separating leadership focus from the formulation engine.
- Acquisition lens: Every API acquisition will be a building block in one integrated company focused on deep capabilities, capacity, chemistry, product portfolio, approvals, and customers, with a focus on niche molecules that are difficult to make and require multiple-step synthesis.
- US FDA ambition: Management will look to incorporate US FDA approvals and access to US markets as part of the larger strategy.
Ashok Nair: "We believe that by combining Ragwa's product and capacity with AKPI's backward integration possibilities, RPG's existing API business systems, processes and governance framework along with our PE partner sector expertise, we can unlock substantially more value than either asset could achieve independently."
The Acquired Assets: Actis and Raghava
- Actis Generics: Acquired for ~₹80 crores including net working capital, Actis brings an intermediates and API manufacturing unit with backward integration and an antidiabetic and cardiovascular portfolio.
- Actis revenue decline: Revenue fell from ₹70 crore to ₹48 crore because of price erosion in one key intermediate; the company has since replaced it with another intermediate carrying a higher margin.
- Actis capacity constraint: The business was at full capacity at ₹48 crores, which limited revenue; management assessed that Actis had limited access to growth capital and a broader commercialization engine, constraining its ability to fully capitalize on market opportunities.
- Actis synergy remedy: Management will utilize available capacity in other group companies like Raghava to ramp up revenue and capacity for Actis, with the ultimate goal of RPG API becoming one entity that shares capacities for a larger play.
- Raghava Life Sciences: Acquired for up to ₹135 crores including net working capital, the facility near Hyderabad has ~300 kg installed capacity, WHO GMP and EU GMP approvals, and 29 molecules of which 22 are commercialized.
- Raghava value unlock: The immediate focus is improving utilization, strengthening commercialization, optimizing product mix, and driving operational efficiencies; the facility has already seen significant investment and comes with modern infrastructure, so no major additional capex is needed.
- Raghava international expansion: With synergy, customer know-how, and cross-sells, management expects to take Raghava's molecules to international markets, particularly the EU.
Operator: "The decline in Actis was not due to any structural issue with the business. In fact the product portfolio or the manufacturing asset. The company continued to maintain strong customer relationship, technical capabilities and highly utilized facility. Our assessment actually indicated that the business had limited access to growth capital and a broader commercialization engine which constrained its ability to fully capitalize on the operational available in the market."
Domestic Formulation: The Steady Engine
- Market-beating consistency: The domestic formulation business, contributing 70% of revenue, has grown 1.3 to 1.8 times the market over the last five quarters, making RPG Life Sciences the fifth fastest growing pharma company in India in the last quarter.
- IPM rank leap: The company advanced 12 IPM ranks from rank 62 in March 2025 to rank 15 in June 2026, entering the top 50 pharma company list.
- Growth acceleration: Domestic formulation has been growing at 12% for the last 3–4 years; this year it grew by 16%, 1.8x the market.
- Organizational restructuring: The formulation business has been segmented into super-specialty businesses with new talent brought in to head them; the marketing and digital team has been strengthened.
- New therapy expansion: A new division has been started in the space of cardiology and urology.
- Management bandwidth dividend: The API carve-out increases management bandwidth for the formulation engine, with focus deepening on both verticals for better overall performance output.
Capital Deployment and Financial Commitments
- ₹700 crore total commitment: The sum is earmarked for the API business, split between acquisitions, capacity building, and improving R&D capabilities, to be deployed over the next 12–15 months for completion of all acquisitions.
- Investment split: Both RPG and Invascent will keep investing as opportunities arise, in proportion to the shareholding pattern; all future commitments will come in the ratios of the shareholding.
- Consolidated cash position: The consolidated entity holds ₹200 crore plus in cash.
- Minority interest impact: The 40% shareholding of RPG Active Pharma will reflect in consolidated financials in the minority interest starting from this quarter.
- Captive sales: Annual captive sales by RPG Active Pharma to RPG Life Sciences are expected to remain in a similar range as last year, around ₹15 crores.
- Valuation discipline: Management expects value creation in terms of valuation multiples being on the higher side of the spectrum versus commodity contracts; acquisitions are being made at prudent valuations with organic sales growth and margin improvement providing large upside for multiple expansion.
Operator: "We would like to be disciplined as far as the capital allocation is concerned."
Margin Trajectory and Near-Term Pressure
- Sustainable margin target: API margins are targeted to be in the mid-20s on a sustainable basis, in the overall range of existing API and company-level margins.
- Near-term pressure acknowledged: Management flagged that there will be pressure on margins in the initial period post-acquisition.
- Synergy-driven improvement: Synergies between Actis, Raghava, and the Navi Mumbai plant are expected to drive higher growth, better margins, and stronger returns on capital through backward integration, manufacturing optimization, capacity utilization, and customer expansion.
- Raghava margin levers: Strengthening business development, increasing utilization, expanding into higher-value markets especially the EU, optimizing product costs, and creating better operating leverage are the identified value unlock levers.
- Current margins undisclosed: Management explicitly declined to disclose the exact EBITDA margins of the API business or current margins at Raghava, stating only that the API business is in the mid-20s range.
Unanswered Questions
- Separate API financials not disclosed: Management stated they are not publishing separate API business numbers as of now, declining to provide headline numbers for sales, EBITDA, PAT, net worth, fixed assets, or working capital for RPG Active Pharma.
- Revenue breakdown by acquired piece not provided: When asked how the three pieces (current API external sales ₹96 crore, Actis ₹48 crore, Raghava ₹19 crore) would grow individually over 3–4 years, management gave only a consolidated 20% CAGR answer without breaking down individual growth drivers.
- Rights issue vs PE valuation gap unexplained: An analyst noted the Invascent investment valued the entity at ~₹600 crore for a 40% stake while the rights issue was at a valuation of ~₹210 crore; management stated the two activities are completely different without explaining the valuation discrepancy.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| API business growth | 25%+ growth CAGR through organic and inorganic interventions | Sustaining over next 5 years |
| Consolidated API CAGR | 20%+ CAGR for the consolidated API business | Next 3–4 years on a sustained basis |
| API revenue aspiration | ₹1,000 crore in the API business | 5–6 years |
| API revenue milestone | Cross ₹200 crores revenue mark | Approximately 2 years |
| Fund deployment | ₹700 crore total commitment deployed for acquisitions and capacity | Next 12–15 months |
| Formulation growth | Grow 1.5x more than the market | Ongoing |
| API margins | Mid-20s on a sustainable basis, with pressure in the initial period post-acquisition | Post initial acquisition pressure period |
| Captive sales | Remain in similar range as last year (~₹15 crores) | Annual |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹95.1 cr (API external third-party sales in FY26) |
| Domestic formulation revenue share | 70% of total revenue |
| International formulation revenue share | 14% of total revenue |
| Domestic formulation growth | 16% in FY26, vs 12% over prior 3–4 years |
| Domestic formulation growth vs market | 1.3–1.8x the market over the last five quarters |
| IPM rank | 15 in June 2026, up from 62 in March 2025 (12-rank improvement) |
| IPM growth ranking | 5th fastest growing pharma company in India (per Match Pharma Prime June 2026) |
| API business EBITDA margin | Mid-20s (management declined to disclose exact figure); expected to remain at similar level with acquisitions |
| API business growth target | 20%+ CAGR on a sustained basis over next 3–4 years; ~25% over next 3–5 years |
| API business long-term revenue aspiration | ₹1,000 cr, to be reached in 5–6 years |
| Combined API installed capacity | ~505 kg, more than fourfold increase from ~110 kg previously |
| API employee strength | Over 500, up from about 217 |
| API R&D scientist team | 53, up from 28 |
| API product portfolio | 45+ products across 13 therapies, up from 14 products across 6 therapies |
| API customer base | Over 250, up from 123 |
| API pipeline molecules | 28, up from 12 |
| Actis Generics acquisition consideration | ~₹80 cr including net working capital |
| Raghava Life Sciences acquisition consideration | Up to ₹135 cr including net working capital |
| Raghava revenue potential at fuller utilization | ~₹200 cr, expected to be crossed in approximately two years |
| Raghava current international revenue share | 15–20%, rest domestic |
| Total planned API investment | ₹700 cr, with ~₹240 cr already committed for Actis and Raghava; balance to be deployed in 12–18 months |
| Invascent stake in RPG Active Pharma | 40% on a fully diluted basis |
| Annual captive API sales to RPG Life Sciences | ~₹15 cr in FY26, expected in similar range |
| Consolidated entity cash position | ₹200 cr plus |